Spark Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (35)

Latest Posts

About This Stock More About This Stock
US Factory Contraction, UK Snap Election To Block Brexit Delay
Article By: Adam Vettese
Wednesday, September 4, 2019 7:47 AM EST
US equity markets fell yesterday as ISM manufacturing data came in weaker than expected. Factory activity data contracted for the first time in 3 years.
In this article: BA, GS, AMZN, TWTR, ONCE, BITCOMP, OIL
Read
3 Promising Gene Therapy Stocks
Article By: Tarun Chandra, CFA
Saturday, May 25, 2019 9:45 PM EST
Investor interest in gene therapy companies has been on the rise. Here is a look at 3 promising small cap gene therapy companies.
In this article: BOLD, VYGR, QURE Also: SRPT, PTCT, BLUE, ONCE, EDIT, NTLA, CRSP, RGNX, SLDB, FIXX, MGTX, NVS, RHHBY, GOOG, ACAD, ARNA, ARRY, CBPO, PCRX, AMRN, SAGE, MRNA, GWPH, ASND, RARX, BHVN, MRTX, DNLI, CHRS, MDCO, ARWR, ZIOP, TGTX, PTLA, GBT, AXSM
Read
Morning Call For Wednesday, Oct. 10
Article By: Jim Van Meerten
Wednesday, October 10, 2018 8:15 AM EST
Dec S&P 500 E-minis (ESZ18 +0.04%) this morning are down -1.25 points (-0.04%).
In this article: FCX, MCD, PPG, WCG, SPX, ONCE
Read
Novartis Q2 Earnings Miss, Sales Top On Cosentyx, Entresto
Article By: Zacks Investment Research
Wednesday, July 18, 2018 11:00 PM EST
Swiss pharma giant Novartis AG reported results for second-quarter 2018, wherein revenues beat estimate, driven by strong performance of Cosentyx and Entresto. However, earnings fell short.
In this article: NVS Also: GSK, ONCE, AMGN, ABBV
Read
Novartis Beats Earnings And Revenue Estimates In Q1
Article By: Zacks Investment Research
Thursday, April 19, 2018 12:14 PM EST
Novartis AG reported encouraging results for first-quarter 2018 wherein both earnings and revenues beat estimates driven by strong performance of Cosentyx and Entresto.
In this article: NVS Also: GSK, ONCE, AVXS
Read

Latest Tweets for $ONCE

No tweets yet!